37.69 USD
+0.56 (+1.51%)
37.69 USD
0 (0%)
We assign a fundamental rating of 7 out of 10 to IBEX. IBEX was compared to 85 industry peers in the IT Services industry. IBEX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. IBEX has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! With these ratings, IBEX could be worth investigating further for value and growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year IBEX was profitable.
IBEX had a positive operating cash flow in the past year.
IBEX had positive earnings in each of the past 5 years.
In the past 5 years IBEX always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 14.58%, IBEX belongs to the top of the industry, outperforming 92.94% of the companies in the same industry.
IBEX has a better Return On Equity (28.81%) than 91.76% of its industry peers.
With an excellent Return On Invested Capital value of 21.63%, IBEX belongs to the best of the industry, outperforming 94.12% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.58% | ||
| ROE | 28.81% | ||
| ROIC | 21.63% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IBEX has a Profit Margin of 7.14%. This is in the better half of the industry: IBEX outperforms 72.94% of its industry peers.
In the last couple of years the Profit Margin of IBEX has grown nicely.
IBEX's Operating Margin of 9.18% is fine compared to the rest of the industry. IBEX outperforms 67.06% of its industry peers.
IBEX's Operating Margin has improved in the last couple of years.
IBEX has a Gross Margin of 30.62%. This is comparable to the rest of the industry: IBEX outperforms 43.53% of its industry peers.
IBEX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 9.18% | ||
| PM (TTM) | 7.14% | ||
| GM | 30.62% |
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IBEX is creating value.
There is no outstanding debt for IBEX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
IBEX has an Altman-Z score of 5.28. This indicates that IBEX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.28, IBEX is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
The Debt to FCF ratio of IBEX is 0.05, which is an excellent value as it means it would take IBEX, only 0.05 years of fcf income to pay off all of its debts.
IBEX's Debt to FCF ratio of 0.05 is amongst the best of the industry. IBEX outperforms 92.94% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that IBEX is not too dependend on debt financing.
IBEX has a better Debt to Equity ratio (0.01) than 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Altman-Z | 5.28 |
ROIC/WACC2.4
WACC9.03%
2.3 Liquidity
IBEX has a Current Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.82, IBEX perfoms like the industry average, outperforming 56.47% of the companies in the same industry.
IBEX has a Quick Ratio of 1.82. This is a normal value and indicates that IBEX is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of IBEX (1.82) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
IBEX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.96%, which is quite impressive.
The Earnings Per Share has been growing by 41.04% on average over the past years. This is a very strong growth
The Revenue has grown by 12.86% in the past year. This is quite good.
The Revenue has been growing slightly by 6.62% on average over the past years.
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
Revenue 1Y (TTM)12.86%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
3.2 Future
The Earnings Per Share is expected to grow by 13.72% on average over the next years. This is quite good.
Based on estimates for the next years, IBEX will show a quite strong growth in Revenue. The Revenue will grow by 9.19% on average per year.
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 11.85, the valuation of IBEX can be described as reasonable.
Based on the Price/Earnings ratio, IBEX is valued cheaply inside the industry as 87.06% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of IBEX to the average of the S&P500 Index (26.54), we can say IBEX is valued rather cheaply.
The Price/Forward Earnings ratio is 10.41, which indicates a very decent valuation of IBEX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of IBEX indicates a rather cheap valuation: IBEX is cheaper than 89.41% of the companies listed in the same industry.
IBEX is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.78, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.85 | ||
| Fwd PE | 10.41 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, IBEX is valued cheaper than 89.41% of the companies in the same industry.
68.24% of the companies in the same industry are more expensive than IBEX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.28 | ||
| EV/EBITDA | 6.8 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
IBEX has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as IBEX's earnings are expected to grow with 13.72% in the coming years.
PEG (NY)0.52
PEG (5Y)0.29
EPS Next 2Y13.72%
EPS Next 3YN/A
5. Dividend
5.1 Amount
IBEX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
37.69
+0.56 (+1.51%)
Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustryIT Services
Earnings (Last)
Earnings (Next)
Inst Owners94.03%
Inst Owner Change-3.84%
Ins Owners2.88%
Ins Owner Change-3.25%
Market Cap507.68M
Revenue(TTM)579.74M
Net Income(TTM)41.38M
Analysts45.71
Price Target39.78 (5.55%)
Short Float %1.11%
Short Ratio1.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.95%
Min EPS beat(2)20.05%
Max EPS beat(2)21.85%
EPS beat(4)4
Avg EPS beat(4)16.83%
Min EPS beat(4)10.89%
Max EPS beat(4)21.85%
EPS beat(8)7
Avg EPS beat(8)12.58%
EPS beat(12)10
Avg EPS beat(12)14.59%
EPS beat(16)12
Avg EPS beat(16)13.3%
Revenue beat(2)2
Avg Revenue beat(2)5.51%
Min Revenue beat(2)2.5%
Max Revenue beat(2)8.52%
Revenue beat(4)4
Avg Revenue beat(4)4.65%
Min Revenue beat(4)2.45%
Max Revenue beat(4)8.52%
Revenue beat(8)5
Avg Revenue beat(8)1.79%
Revenue beat(12)5
Avg Revenue beat(12)-0.35%
Revenue beat(16)7
Avg Revenue beat(16)-0.06%
PT rev (1m)1.3%
PT rev (3m)27.87%
EPS NQ rev (1m)-2.48%
EPS NQ rev (3m)1.29%
EPS NY rev (1m)5.47%
EPS NY rev (3m)10.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.79%
Revenue NY rev (1m)1.82%
Revenue NY rev (3m)6.62%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.85 | ||
| Fwd PE | 10.41 | ||
| P/S | 0.88 | ||
| P/FCF | 16.28 | ||
| P/OCF | 9.48 | ||
| P/B | 3.53 | ||
| P/tB | 3.85 | ||
| EV/EBITDA | 6.8 |
EPS(TTM)3.18
EY8.44%
EPS(NY)3.62
Fwd EY9.61%
FCF(TTM)2.32
FCFY6.14%
OCF(TTM)3.98
OCFY10.55%
SpS43.04
BVpS10.66
TBVpS9.78
PEG (NY)0.52
PEG (5Y)0.29
Graham Number27.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.58% | ||
| ROE | 28.81% | ||
| ROCE | 26.64% | ||
| ROIC | 21.63% | ||
| ROICexc | 24.4% | ||
| ROICexgc | 26.15% | ||
| OM | 9.18% | ||
| PM (TTM) | 7.14% | ||
| GM | 30.62% | ||
| FCFM | 5.38% |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y27.75%
OM growth 5Y12.6%
PM growth 3Y14.82%
PM growth 5Y27.95%
GM growth 3Y0.55%
GM growth 5YN/A
F-Score8
Asset Turnover2.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.05 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 129.83% | ||
| Cap/Sales | 3.86% | ||
| Interest Coverage | 31.53 | ||
| Cash Conversion | 76.01% | ||
| Profit Quality | 75.39% | ||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z | 5.28 |
F-Score8
WACC9.03%
ROIC/WACC2.4
Cap/Depr(3y)83.97%
Cap/Depr(5y)108.52%
Cap/Sales(3y)2.89%
Cap/Sales(5y)3.72%
Profit Quality(3y)75.63%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.96%
EPS 3Y28.16%
EPS 5Y41.04%
EPS Q2Q%73.08%
EPS Next Y22.95%
EPS Next 2Y13.72%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)12.86%
Revenue growth 3Y4.24%
Revenue growth 5Y6.62%
Sales Q2Q%16.55%
Revenue Next Year12.81%
Revenue Next 2Y9.19%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y23.48%
EBIT growth 3Y33.16%
EBIT growth 5Y20.06%
EBIT Next Year68.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.26%
FCF growth 3Y24.66%
FCF growth 5Y-10.09%
OCF growth 1Y19.11%
OCF growth 3Y4.51%
OCF growth 5Y-2.46%
IBEX LTD / IBEX FAQ
Can you provide the ChartMill fundamental rating for IBEX LTD?
ChartMill assigns a fundamental rating of 7 / 10 to IBEX.
Can you provide the valuation status for IBEX LTD?
ChartMill assigns a valuation rating of 8 / 10 to IBEX LTD (IBEX). This can be considered as Undervalued.
What is the profitability of IBEX stock?
IBEX LTD (IBEX) has a profitability rating of 7 / 10.
Can you provide the financial health for IBEX stock?
The financial health rating of IBEX LTD (IBEX) is 7 / 10.
Can you provide the expected EPS growth for IBEX stock?
The Earnings per Share (EPS) of IBEX LTD (IBEX) is expected to grow by 22.95% in the next year.